Eliem Therapeutics (ELYM)
US Market

Eliem Therapeutics (ELYM) Stock Price & Analysis


ELYM Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.21 - $5.20
Previous Close$3
Average Volume (3M)10.89K
Market Cap
Enterprise Value-$27.70M
Total Cash (Recent Filing)$109.37M
Total Debt (Recent Filing)$687.00K
Price to Earnings (P/E)-1.5
Sep 11, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.06
Shares Outstanding26,993,401
10 Day Avg. Volume4,525
30 Day Avg. Volume10,895
Standard Deviation0.22
Financial Highlights & Ratios
Price to Book (P/B)0.69
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.52
Price Target Upside66.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Eliem Therapeutics’s price range in the past 12 months?
Eliem Therapeutics lowest stock price was $2.21 and its highest was $5.20 in the past 12 months.
    What is Eliem Therapeutics’s market cap?
    Currently, no data Available
    When is Eliem Therapeutics’s upcoming earnings report date?
    Eliem Therapeutics’s upcoming earnings report date is Sep 11, 2023 which is in 104 days.
      How were Eliem Therapeutics’s earnings last quarter?
      Eliem Therapeutics released its earnings results on May 11, 2023. The company reported -$0.84 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.59.
        Is Eliem Therapeutics overvalued?
        According to Wall Street analysts Eliem Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Eliem Therapeutics pay dividends?
          Eliem Therapeutics does not currently pay dividends.
          What is Eliem Therapeutics’s EPS estimate?
          Eliem Therapeutics’s EPS estimate is -$0.25.
            How many shares outstanding does Eliem Therapeutics have?
            Eliem Therapeutics has 26,993,400 shares outstanding.
              What happened to Eliem Therapeutics’s price movement after its last earnings report?
              Eliem Therapeutics reported an EPS of -$0.84 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went down -4.192%.
                Which hedge fund is a major shareholder of Eliem Therapeutics?
                Among the largest hedge funds holding Eliem Therapeutics’s share is RA Capital Management. It holds Eliem Therapeutics’s shares valued at 38M.


                  Eliem Therapeutics Stock Smart Score

                  The Eliem Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Eliem Therapeutics

                  Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.


                  Top 5 ETFs holding ELYM

                  Currently, no data available
                  Please return soon. This page is being updated.
                  Up to five ETFs with an Outperform Smart Score that hold ELYM. The ETFs are listed according to market value of ELYM within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Pieris Pharmaceuticals
                  Frequency Therapeutics
                  SQZ Biotechnologies
                  Armata Pharmaceuticals
                  Galectin Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis